english.prescrire.org > Spotlight > 100 most recent > Dulaglutide, exenatide, liraglutide and other GLP-1 receptor agonists: thyroid cancer

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Dulaglutide, exenatide, liraglutide and other GLP-1 receptor agonists: thyroid cancer

 Adverse Effects  In 2022, a French research team published a case-control study which investigated the association between exposure to a GLP-1 receptor agonist and the risk of developing thyroid cancer.
Full article available for download by subscribers

2562 patients with type 2 diabetes, identified in the French National Health Data System (SNDS), had been treated in hospital for thyroid cancer (or had been reimbursed by the mandatory national health insurance system for treatment for this disease) between 2014 and 2018. They were compared to 45 184 diabetic controls without thyroid cancer.

The proportion of patients with thyroid cancer who were exposed to a GLP-1 agonist was about 1.5 times greater than in the control group without cancer.

This adverse effect should be taken into account with all GLP-1 receptor agonists, whether they are used for diabetes or weight loss.

©Prescrire 1 September 2023

Source: "Dulaglutide, exenatide, liraglutide and other GLP-1 receptor agonists: thyroid cancer" Prescrire International 2023; 32 (251): 215. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >